LOGIN  |  REGISTER
Cue Biopharma
Terns Pharmaceuticals

ICU Medical to Participate in Upcoming Investor Conferences

August 21, 2024 | Last Trade: US$127.73 0.33 0.26

SAN CLEMENTE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the following investor conferences in September:

Wells Fargo 2024 Healthcare Conference on September 4, 2024

Vivek Jain, Chief Executive Officer, will attend one-on-one meetings at the Wells Fargo 2024 Healthcare Conference in Boston on Wednesday, September 4, 2024.

Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024

Vivek Jain, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on Friday, September 6, 2024. The discussion will begin at 4:00 a.m. PT (7:00 a.m. ET) and will be webcast live on the Event Calendar section of the Company’s Investor Relations website at https://ir.icumed.com. A replay of the webcast will be archived on the website for future viewing. Company management will also participate in one-on-one meetings at the conference.

About ICU Medical

ICU Medical (Nasdaq:ICUI) is a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our team is focused on providing quality, innovation and value to our clinical customers worldwide. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical can be found at www.icumed.com

CONTACT:
ICU Medical
Brian Bonnell, Chief Financial Officer
(949) 366-2183

ICR, Inc.
John Mills, Managing Partner
(646) 277-1254

Viking Therapeutics

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page